NASDAQ$PTGX
Protagonist Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported second quarter financial results and provided corporate update.
Protagonist Therapeutics reported its second quarter financial results, highlighting the advancement of three differentiated candidates into Phase 2 development and a successful secondary offering and ATM program, ensuring financial resources to support operations through mid-2023.
- Three differentiated candidates advanced from de novo discovery into Phase 2 development.
- PTG-300 received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of polycythemia vera.
- Expect to initiate a pivotal study for PTG-300 in 2021 after discussions with the regulatory agencies.
- Financial resources expected to support operations through mid-2023.
Headline financials
Revenue & EPS history
Protagonist · Revenue · Quarterly
$6.22M
Forward guidance
Protagonist Therapeutics anticipates continued progress in its clinical programs and expects financial resources to support operations through mid-2023.
Tailwinds
- Potential of ongoing clinical programs
- Plans for future clinical trials
- Potential of PTG-300 as a possible treatment for polycythemia vera and other blood disorders
- Potential of PTG-200 and PN-943 as possible treatments for inflammatory bowel disease
- Potential of a pivotal study for PTG-300 in 2021
Headwinds
- Ability to develop and commercialize product candidates
- Ability to earn milestone payments under collaboration agreement with Janssen Biotech
- Ability to use and expand programs to build a pipeline of product candidates
- Ability to obtain and maintain regulatory approval of product candidates
- Risks related to the global COVID-19 pandemic and actions taken to slow its spread
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+3.2%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+8.3%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+75.1%
Q1 2020
Best reaction
-21.2%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -0.2% | +3.3% | |
| Q4 2025 | -0.3% | +7.8% | +13.3% | |
| Q3 2025 | -0.2% | +6.4% | +12.4% | |
| Q1 2025 | +2.4% | +3.2% | +22.9% | |
| Q4 2024 | -7.1% | -6.2% | +35.6% | |
| Q3 2024 | -2.9% | -9.3% | -11.6% | |
| Q2 2024 | +0.0% | +8.2% | +17.4% | |
| Q1 2024 | +4.0% | +8.3% | +30.5% | |
| Q4 2023 | +3.0% | +8.9% | -2.0% | |
| Q3 2023 | +10.2% | +9.0% | +22.8% | |
| Q2 2023 | +3.3% | -2.0% | +5.2% | |
| Q1 2023 | +1.5% | +3.3% | +15.3% | |
| Q4 2022 | -8.4% | -9.9% | -25.9% | |
| Q3 2022 | -0.5% | +9.4% | +0.4% | |
| Q2 2022 | +2.2% | -1.6% | -21.1% | |
| Q1 2022 | -0.3% | -10.3% | -6.4% | |
| Q4 2021 | +7.2% | -0.7% | -2.3% | |
| Q3 2021 | +5.0% | +7.4% | +0.1% | |
| Q2 2021 | -2.2% | -0.4% | -0.8% | |
| Q1 2021 | -0.4% | -0.1% | +19.3% | |
| Q4 2020 | +3.5% | +2.8% | -11.4% | |
| Q3 2020 | +14.2% | +6.6% | +11.0% | |
| Q2 2020 | +8.3% | +2.3% | +23.8% | |
| Q1 2020 | +75.1% | +97.4% | +98.0% | |
| Q4 2019 | -4.8% | +5.1% | -7.6% | |
| Q3 2019 | -19.3% | -14.2% | -37.5% | |
| Q2 2019 | +0.8% | -2.9% | +60.6% | |
| Q1 2019 | +20.8% | +16.3% | +31.4% | |
| Q4 2018 | +0.1% | +22.3% | +22.2% | |
| Q3 2018 | +14.1% | +22.3% | -14.6% | |
| Q2 2018 | -1.8% | -6.4% | -18.1% | |
| Q1 2018 | -21.2% | -22.4% | -13.5% | |
| Q4 2017 | -2.0% | +1.4% | -57.5% | |
| Q3 2017 | +8.9% | +16.2% | +25.2% | |
| Q2 2017 | -7.7% | -4.4% | +33.6% | |
| Q1 2017 | +10.5% | +14.3% | +21.1% | |
| Q4 2016 | -0.6% | +0.4% | -16.8% | |
| Q3 2016 | -1.6% | +3.4% | -16.5% | |
| Q2 2016 | +9.4% | +19.1% | +63.8% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro